Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma Drainage Implants | 4 | 2024 | 6 | 1.860 |
Why?
|
| Glaucoma, Open-Angle | 7 | 2024 | 21 | 1.820 |
Why?
|
| Glaucoma | 6 | 2024 | 34 | 1.690 |
Why?
|
| Intraocular Pressure | 14 | 2024 | 55 | 1.650 |
Why?
|
| Glaucoma, Angle-Closure | 3 | 2023 | 3 | 1.080 |
Why?
|
| Visual Acuity | 6 | 2024 | 138 | 1.050 |
Why?
|
| Trabeculectomy | 6 | 2024 | 10 | 1.020 |
Why?
|
| Laser Therapy | 3 | 2021 | 84 | 0.990 |
Why?
|
| Retinoschisis | 1 | 2023 | 3 | 0.890 |
Why?
|
| Sutures | 2 | 2020 | 40 | 0.880 |
Why?
|
| Eye Diseases | 1 | 2023 | 38 | 0.860 |
Why?
|
| Lasers, Solid-State | 2 | 2020 | 32 | 0.830 |
Why?
|
| Retinal Diseases | 1 | 2023 | 50 | 0.820 |
Why?
|
| Prosthesis Implantation | 2 | 2024 | 46 | 0.750 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2020 | 21 | 0.690 |
Why?
|
| Iridectomy | 1 | 2019 | 1 | 0.680 |
Why?
|
| Iris | 1 | 2019 | 5 | 0.680 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2016 | 6 | 0.550 |
Why?
|
| Anticoagulants | 1 | 2019 | 253 | 0.550 |
Why?
|
| Pupil Disorders | 1 | 2016 | 4 | 0.540 |
Why?
|
| Visual Fields | 4 | 2024 | 37 | 0.420 |
Why?
|
| Gonioscopy | 2 | 2024 | 3 | 0.410 |
Why?
|
| Contrast Sensitivity | 3 | 2019 | 6 | 0.370 |
Why?
|
| Retina | 2 | 2023 | 65 | 0.370 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2190 | 0.290 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 3154 | 0.270 |
Why?
|
| Male | 14 | 2024 | 25399 | 0.260 |
Why?
|
| Humans | 20 | 2024 | 50208 | 0.260 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5155 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6134 | 0.250 |
Why?
|
| Middle Aged | 10 | 2024 | 12206 | 0.240 |
Why?
|
| Aged | 11 | 2024 | 9405 | 0.240 |
Why?
|
| Uveitis | 1 | 2024 | 29 | 0.240 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 40 | 0.220 |
Why?
|
| Quality of Life | 2 | 2019 | 839 | 0.220 |
Why?
|
| Vision Tests | 2 | 2019 | 13 | 0.200 |
Why?
|
| Acute Disease | 1 | 2023 | 368 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2020 | 2379 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 201 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1126 | 0.190 |
Why?
|
| Filtering Surgery | 1 | 2020 | 1 | 0.190 |
Why?
|
| Female | 12 | 2024 | 26635 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2024 | 657 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 2 | 2024 | 102 | 0.180 |
Why?
|
| Trabecular Meshwork | 1 | 2019 | 3 | 0.180 |
Why?
|
| Electroretinography | 1 | 2019 | 15 | 0.170 |
Why?
|
| Exfoliation Syndrome | 1 | 2019 | 2 | 0.170 |
Why?
|
| Postoperative Period | 1 | 2020 | 168 | 0.170 |
Why?
|
| Postoperative Complications | 3 | 2024 | 996 | 0.170 |
Why?
|
| Ophthalmology | 1 | 2019 | 31 | 0.170 |
Why?
|
| Vision, Ocular | 1 | 2019 | 11 | 0.170 |
Why?
|
| Vision Disorders | 1 | 2019 | 57 | 0.160 |
Why?
|
| Surgically-Created Structures | 1 | 2018 | 1 | 0.160 |
Why?
|
| Trypan Blue | 1 | 2018 | 6 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 173 | 0.150 |
Why?
|
| Risk Factors | 4 | 2024 | 3629 | 0.150 |
Why?
|
| Coloring Agents | 1 | 2018 | 70 | 0.150 |
Why?
|
| Cataract | 1 | 2018 | 45 | 0.150 |
Why?
|
| Phacoemulsification | 1 | 2018 | 31 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 486 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 205 | 0.150 |
Why?
|
| Medical Illustration | 1 | 2016 | 6 | 0.140 |
Why?
|
| Iris Diseases | 1 | 2016 | 4 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 486 | 0.140 |
Why?
|
| Syndrome | 1 | 2016 | 238 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1554 | 0.130 |
Why?
|
| Child | 3 | 2023 | 6851 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2019 | 441 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 27 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 63 | 0.110 |
Why?
|
| Time Factors | 1 | 2019 | 2922 | 0.110 |
Why?
|
| Cross Infection | 1 | 2013 | 93 | 0.100 |
Why?
|
| Pneumonia | 1 | 2012 | 118 | 0.100 |
Why?
|
| Sickness Impact Profile | 2 | 2019 | 28 | 0.080 |
Why?
|
| Visual Field Tests | 2 | 2019 | 13 | 0.080 |
Why?
|
| Adult | 6 | 2024 | 13324 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 747 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1185 | 0.060 |
Why?
|
| Blindness | 1 | 2023 | 31 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 3981 | 0.060 |
Why?
|
| United States | 2 | 2024 | 4874 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 249 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 123 | 0.050 |
Why?
|
| Registries | 1 | 2023 | 522 | 0.050 |
Why?
|
| Pilocarpine | 1 | 2020 | 25 | 0.050 |
Why?
|
| Incidence | 1 | 2024 | 1006 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 268 | 0.050 |
Why?
|
| Prevalence | 1 | 2023 | 951 | 0.050 |
Why?
|
| Health Surveys | 1 | 2020 | 232 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 310 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 688 | 0.040 |
Why?
|
| Tonometry, Ocular | 1 | 2018 | 5 | 0.040 |
Why?
|
| Alkylating Agents | 1 | 2018 | 23 | 0.040 |
Why?
|
| Mitomycin | 1 | 2018 | 20 | 0.040 |
Why?
|
| Conjunctiva | 1 | 2018 | 13 | 0.040 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2018 | 22 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2018 | 97 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 351 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 695 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2019 | 392 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 831 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 636 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 6390 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 688 | 0.030 |
Why?
|
| Brazil | 1 | 2013 | 35 | 0.030 |
Why?
|
| Penicillins | 1 | 2013 | 28 | 0.030 |
Why?
|
| Carbapenems | 1 | 2013 | 17 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 53 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2013 | 41 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 76 | 0.030 |
Why?
|
| Quinolones | 1 | 2013 | 39 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 39 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 905 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 889 | 0.020 |
Why?
|